Interestingly, the analysis conducted across 19 studies demonstrated that CEA-based panels—combining markers such as CEA, CA19-9, CA125, CA50 (cancer antigen 50), and CA242 (cancer antigen 242) in various configurations—provided greater diagnostic accuracy for pancreatic cancer than CEA or CA19-9 alone [44]. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.